Ivabradine Demo

Ivabradine, the active ingredient in Ivabradine Demo, is a If channel inhibitor presented as a tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction. GNH USA supplies Ivabradine Demo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current, a pathway central to heart rate regulation in several cardiovascular conditions. - Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers resting heart rate, which can alleviate symptoms and may improve functional capacity. - Coronary artery disease (symptomatic): helps control heart rate when beta‑blockers are insufficient or contraindicated.

Ivabradine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Bradycardia: resting heart rate below 50 bpm. - Visual disturbances: luminous phenomena (phosphenes) or blurred vision. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Nausea.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Heart block or advanced atrioventricular conduction disturbances. - Severe hypotension. - Visual loss or persistent visual impairment. - Allergic reactions such as rash, pruritus, or anaphylaxis.

Before initiating ivabradine, clinicians should evaluate cardiac status and concomitant therapies. - Heart rate monitoring: confirm resting heart rate ≥ 60 bpm before starting. - Concomitant beta‑blockers: avoid excessive bradycardia by adjusting doses. - Strong CYP3A4 inhibitors: consider dose reduction or alternative therapy. - Severe hepatic impairment: use with caution; benefits may not outweigh risks. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ivabradine can interact with several drug classes, influencing heart rate or plasma concentrations.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels, raising bradycardia risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can markedly reduce efficacy. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - Antacids or drugs that alter gastric pH: can affect absorption; separate administration by at least 2 hours. - Alcohol: may potentiate bradycardic effects. - Electrolyte disturbances (e.g., hypokalemia): increase arrhythmia susceptibility.